Home › Acute Myeloid Leukemia › Oklahoma
Acute Myeloid Leukemia clinical trials in Oklahoma
15 studies for Acute Myeloid Leukemia are looking for participants at sites in Oklahoma.
Cities in Oklahoma
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Nov 9, 2026 · NCT05554406Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Nov 6, 2026 · NCT07437950Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT05564390Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Oct 28, 2026 · NCT05554393Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06672146A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
6 Months – 21 Years · All sexes · Updated Sep 17, 2026 · NCT04293562The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Aug 25, 2026 · NCT05886049Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Oklahoma Health Science Center, Oklahoma City
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545Pilot Imaging Study of Leukemia
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 1
Ages 4 to 80 · All sexes · Updated Apr 23, 2026 · NCT03633955A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 29, 2024 · NCT04905810From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.